Global Systemic Psoriasis Therapeutics Market to grow at a CAGR of 9.41% during 2016-2020

MarketResearchReports.Biz has announced addition of new report “Global Systemic Psoriasis Therapeutics Market 2016-2020” to its database.

About the Systemic Psoriasis Therapeutics Market

Psoriasis is a commonly diagnosed immune-mediated disease of the skin. In psoriasis, the skin grows fast and causes a build-up of red, thick white, or silvery patches. It modifies the normal cell cycle of the skin such that new cells move to the surface of the skin quickly to form patches called plaques. These plaques are commonly found on the knees, elbows, scalp, hand and feet. The condition mostly occurs among adults (18 years-35 years), but can also be seen in adolescents (12 years-18 years) and children (under 10 years).

Psoriasis is more prevalent among Caucasians compared to African-Americans. According to a World Health Organization (WHO) document of 2015, the global prevalence of psoriasis is approximately 2%-3%. However, it is approximately 4.6% in developed countries. In addition, the risk of an individual getting diagnosed with psoriasis is 41% if both parents have psoriasis, 14% in case one parent is affected, and 6% if a sibling has psoriasis.

Technavios analysts forecast the global systemic psoriasis therapeutics market to grow at a CAGR of 9.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global systemic psoriasis therapeutics market for 2016-2020. To calculate the market size, Technavio considers the revenue generated from the from the sales of branded, generic, and off-label drugs used to treat psoriasis. It also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the patent expiries of marketed drugs during the forecast period.

The market is divided into the following segments based on geography:




Technavio’s report, Global Systemic Psoriasis Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.


Key vendors


Johnson & Johnson




Download Sample Copy of Report at


Other prominent vendors



Anacor Pharmaceuticals


Astellas Pharma


Aurinia Pharmaceuticals


Biogen Idec


Boehringer Ingelheim

Bristol-Myers Squibb

Can-Fite BioPharma

Cellceutix Corporation

Coherus Biosciences


Crescendo Biologics

Delenex Therapeutics


Eli Lilly

  1. Hoffmann-La Roche

Forward Pharma

G & W Laboratories


Idera Pharmaceuticals




KPI Therapeutics

Kyowa Hakko Kirin

LEO Pharma



Mitsubishi Tanabe Pharma




Prism Pharma

Promius Pharma

Prothena Biosciences

Provectus Biopharmaceuticals


Sun Pharmaceuticals

Takeda Pharmaceuticals

Taro Pharmaceuticals



Valeant Pharmaceuticals

VBL Therapeutics


Ziarco Pharma


Market driver

Dominance of market by biologics

For a full, detailed list, view our report


Market challenge

Physician’s reluctance to prescribe biosimilars

For a full, detailed list, view our report


Market trend

Advent of biologics with novel MOA and cell-based strategies

For a full, detailed list, view our report


Key questions answered in this report

What will the market size be in 2020 and what will the growth rate be?

What are the key market trends?

What is driving this market?

What are the challenges to market growth?

Who are the key vendors in this market space?

What are the market opportunities and threats faced by the key vendors?

What are the strengths and weaknesses of the key vendors?

%d bloggers like this: